0001193125-22-096828.txt : 20220406 0001193125-22-096828.hdr.sgml : 20220406 20220406075006 ACCESSION NUMBER: 0001193125-22-096828 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220406 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220406 DATE AS OF CHANGE: 20220406 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oaktree Acquisition Corp. II CENTRAL INDEX KEY: 0001820931 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 981551592 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39526 FILM NUMBER: 22809387 BUSINESS ADDRESS: STREET 1: C/O OAKTREE CAPITAL MANAGEMENT, L.P. STREET 2: 333 S. GRAND AVENUE, 28TH FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90071 BUSINESS PHONE: 213-830-6300 MAIL ADDRESS: STREET 1: C/O OAKTREE CAPITAL MANAGEMENT, L.P. STREET 2: 333 S. GRAND AVENUE, 28TH FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90071 FORMER COMPANY: FORMER CONFORMED NAME: Oaktree Acquisition Corp II. DATE OF NAME CHANGE: 20200812 8-K 1 d345191d8k.htm 8-K 8-K
false 0001820931 0001820931 2022-04-06 2022-04-06 0001820931 us-gaap:CapitalUnitsMember 2022-04-06 2022-04-06 0001820931 us-gaap:CommonClassAMember 2022-04-06 2022-04-06 0001820931 us-gaap:WarrantMember 2022-04-06 2022-04-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 6, 2022

 

 

Oaktree Acquisition Corp. II

(Exact Name of Registrant as Specified in Charter)

 

 

 

Cayman Islands   001-39526   98-1551592

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

333 South Grand Avenue

28th Floor

Los Angeles, CA 90071

(Address of Principal Executive Offices, and Zip Code)

(213) 830-6300

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☒

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fourth of one redeemable warrant   OACB.U   New York Stock Exchange
Class A ordinary shares included as part of the units   OACB   New York Stock Exchange
Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50   OACB WS   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 7.01.

Regulation FD Disclosure.

On April 6, 2022, Alvotech Holdings S.A. issued a press release announcing the resolution of litigation with AbbVie Inc. in Europe and selected markets outside of Europe. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The foregoing (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act.

Additional Information

In connection with the proposed business combination (the “Business Combination”) between Oaktree Acquisition Corp. II (“OACB”) and Alvotech Holdings S.A. (“Alvotech”). OACB and Alvotech have filed with the U.S. Securities and Exchange Commission (the “SEC”) a Registration Statement on Form F-4 (the “Registration Statement”) containing a preliminary proxy statement of OACB and a preliminary prospectus of Alvotech Lux Holdings S.A.S., and after the Registration Statement is declared effective, OACB will mail a definitive proxy statement/prospectus related to the proposed Business Combination to its shareholders. This Current Report on Form 8-K does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the proposed Business Combination. OACB’s shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about Alvotech, OACB and the proposed Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to shareholders of OACB as of a record date to be established for voting on the proposed Business Combination. Shareholders of OACB will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a written request to: OACB, 333 South Grand Avenue, 28th Floor, Los Angeles, California 90071.

Participants in the Solicitation

OACB and Alvotech and their directors and executive officers may be deemed participants in the solicitation of proxies from OACB’s shareholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in OACB is contained in OACB’s annual report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC and is available free of charge at the SEC’s web site at www.sec.gov, or by directing a written request to OACB, 333 South Grand Avenue, 28th Floor, Los Angeles, California 90071. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed Business Combination when available.

Alvotech Lux Holdings S.A.S and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of OACB in connection with the proposed Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed Business Combination will be included in the proxy statement/prospectus for the proposed Business Combination when available.

Forward Looking Statements

Certain statements in this Current Report on Form 8-K may be considered “forward-looking statements.” Forward-looking statements generally relate to future events or the future financial operating performance of OACB or Alvotech. For example, Alvotech’s expectations regarding future growth, results of operations, performance, future capital and other expenditures including the development of critical infrastructure for the global healthcare markets, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events; and the potential approval and commercial launch of AVT02. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by OACB and its management, and Alvotech and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond OACB’s and Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against OACB, the combined company or others following this announcement of the Business Combination and any

definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of OACB, to obtain financing to complete the Business Combination or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Alvotech as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain key relationships and retain its management and key employees; (8) costs related to the Business Combination; (9) changes in applicable laws or regulations; (10) the possibility that Alvotech or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) Alvotech’s estimates of expenses and profitability; (12) pending litigation related to AVT02; (13) the potential impact of the ongoing COVID-19 pandemic on the FDA’s review timelines, including its ability to complete timely inspection of manufacturing sites; (13) the commercial launch date of AVT02 in the United States or elsewhere, and (15) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in OACB’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2020 (as amended December 13, 2021) or in other documents filed by OACB with the SEC. There may be additional risks that neither OACB nor Alvotech presently know or that OACB and Alvotech currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this Current Report on Form 8-K should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither OACB nor Alvotech undertakes any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this Current Report on Form 8-K. Alvotech and OACB disclaim any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this Current Report on Form 8-K and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech, OACB or any of their respective directors, officers, employees, affiliates, agents, advisors or representatives liable in any respect for the provision of this Current Report on Form 8-K, the information contained in this Current Report on Form 8-K, or the omission of any information from this Current Report on Form 8-K.

No Offer

This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.   

Description of Exhibit

99.1    Press Release, dated April 6, 2022
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    OAKTREE ACQUISITION CORP. II
Date: April 6, 2022     By:  

/s/ Zaid Pardesi

      Name:   Zaid Pardesi
      Title:   Chief Financial Officer and Head of M&A
 EX-99.1 2 d345191dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    LOGO

 

Press release

Alvotech and STADA pave way to launching HUKYNDRA®(AVT02), a citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie

 

  •  

Upon launch, HUKYNDRA® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market

 

  •  

All intellectual-property disputes related to market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved

Reykjavik, Iceland & Bad Vilbel, Germany. April 6, 2022 – Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, has today announced the resolution of all intellectual property disputes with AbbVie in Europe and selected markets outside of Europe, related to its AVT02 biosimilar candidate. This paves the way for Alvotech’s exclusive strategic partner STADA to commercialize AVT02, a citrate-free, high-concentration (100 mg/mL) biosimilar to Humira® (adalimumab) in European countries under the HUKYNDRA® brand name.

Under the terms of the European patent resolution, AbbVie has granted Alvotech a non-exclusive, royalty bearing license to AbbVie’s intellectual property relating to Humira® in Europe and in selected markets outside of Europe, thus paving the way for greater patient access to adalimumab.

“This resolution is an important step in Alvotech’s mission to bring more sustainable healthcare to patients in need and we look forward to launching our first biosimilar in the European market with STADA,” said Robert Wessman, Founder and Chairman of Alvotech.

 

STADA Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Simone Berger / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au

04/06/2021    Caring for People’s Health    Page 1 of 7

LOGO    LOGO

 

With all intellectual-property issues now resolved, STADA is preparing to launch the HUKYNDRA citrate-free, high-concentration biosimilar broadly across Europe. STADA is Alvotech’s exclusive strategic partner for commercializing AVT02 in Europe and selected other territories.

“HUKYNDRA will be the first of what we anticipate will be a continuous stream of biosimilar launches across a broad range of therapeutic categories through our partnership with Alvotech.,” said Peter Goldschmidt, CEO of STADA. “We are committed to working with partners to bring competition to the biologic medicines sector, thereby delivering value and facilitating patient access.”

HUKYNDRA is the first of seven molecules covered by an exclusive biosimilars agreement signed between Alvotech and STADA in November 2019. This broad partnership includes biosimilar candidates aimed at treating autoimmunity, oncology, and ophthalmology conditions.

In December 2021, the partners announced that they had received approval from the European Commission for AVT02 (adalimumab), now called HUKYNDRA in Europe, the company’s citrate-free, 100 mg/mL high concentration biosimilar to Humira®, for the 27 member countries of the European Union plus Norway, Iceland and Liechtenstein.

HUKYNDRA is authorized for use in treating a range of inflammatory conditions including rheumatoid arthritis, plaque psoriasis and Crohn’s disease. Adalimumab inhibits tumor necrosis factor alpha, which is a protein in the body involved in inflammation. Humira® was the highest grossing medicine in the world in 2021 (excluding COVID-19 vaccines) with global sales of over $20 billion.

 

STADA Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Simone Berger / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au

04/06/2021    Caring for People’s Health    Page 2 of 7

LOGO    LOGO

 

In February 2022, the US Food and Drug Administration (FDA) accepted for review a Biologics Licensing Application (BLA) for ATV02 (100 mg/mL), Alvotech’s citrate-free, high-concentration biosimilar, that includes new data supporting interchangeability between ATV02 and Humira®, for the U.S. market. The application was supported by positive results from a switching study that demonstrates bioequivalence and comparable efficacy, safety and immunogenicity of repeated switches between administration of Humira® and AVT02.

On December 7, 2021, Alvotech and Oaktree Acquisition Corp. II (NYSE: OACB.U, OACB, OACB WS), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P., announced they had entered into a definitive business combination agreement. Upon completion of the transaction, the combined company’s securities are expected to be traded on NASDAQ under the symbol “ALVO.”

About Alvotech

Alvotech is a biopharmaceutical company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, asthma and cancer. For more information, please visit www.alvotech.com.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2021, STADA achieved group sales of EUR 3,249.5 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 776.5 million. As of 31 December 2021, STADA employed 12,520 people worldwide.

About AVT02

AVT02 is a monoclonal antibody and a biosimilar to Humira® (adalimumab). AVT02 is not approved outside of the EU (Hukyndra®), Canada (Simlandi™), and the United Kingdom (Hukyndra®). AVT02 dossiers are under review in multiple countries; in the U.S. the BLA is in deferred status, pending FDA inspection(s).

 

STADA Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Simone Berger / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au

04/06/2021    Caring for People’s Health    Page 3 of 7

LOGO    LOGO

 

Additional Information

In connection with the proposed business combination (the “Business Combination”) between OACB and Alvotech. OACB and Alvotech have filed with the U.S. Securities and Exchange Commission (the “SEC”) a Registration Statement on Form F-4 (the “Registration Statement”) containing a preliminary proxy statement of OACB and a preliminary prospectus of Alvotech Lux Holdings S.A.S., and after the Registration Statement is declared effective, OACB will mail a definitive proxy statement/prospectus related to the proposed Business Combination to its shareholders. This communication does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the proposed Business Combination. OACB’s shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about Alvotech, OACB and the proposed Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to shareholders of OACB as of a record date to be established for voting on the proposed Business Combination. Shareholders of OACB will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a written request to: OACB, 333 South Grand Avenue, 28th Floor, Los Angeles, California 90071.

Participants in the Solicitation

OACB and Alvotech and their directors and executive officers may be deemed participants in the solicitation of proxies from OACB’s shareholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in OACB is contained in OACB’s annual report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC and is available free of charge at the SEC’s web site at www.sec.gov, or by directing a written request to OACB, 333 South Grand Avenue, 28th Floor, Los Angeles, California 90071. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed Business Combination when available.

Alvotech Lux Holdings S.A.S and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of OACB in connection with the proposed Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed Business Combination will be included in the proxy statement/prospectus for the proposed Business Combination when available.

Forward-Looking Statement

Certain statements in this communication may be considered “forward-looking statements.” Forward-looking statements generally relate to future events or the future financial operating performance of OACB or Alvotech. For example, Alvotech’s expectations regarding future growth, results of operations, performance, future capital and other expenditures including the

 

STADA Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Simone Berger / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au

04/06/2021    Caring for People’s Health    Page 4 of 7

LOGO    LOGO

 

development of critical infrastructure for the global healthcare markets, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events; and the potential approval and commercial launch of AVT02. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by OACB and its management, and Alvotech and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond OACB’s and Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against OACB, the combined company or others following this announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of OACB, to obtain financing to complete the Business Combination or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Alvotech as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain key relationships and retain its management and key employees; (8) costs related to the Business Combination; (9) changes in applicable laws or regulations; (10) the possibility that Alvotech or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) Alvotech’s estimates of expenses and profitability; (12) pending litigation related to AVT02; (13) the potential impact of the ongoing COVID-19 pandemic on the FDA’s review timelines, including its ability to complete timely inspection of manufacturing sites; (14) the commercial launch of AVT02 in Canada, the United States, Europe or elsewhere; and (15) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in OACB’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 or in other documents filed by OACB with the SEC. There may be additional risks that neither OACB nor Alvotech presently know or that OACB and Alvotech currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-

 

STADA Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Simone Berger / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au

04/06/2021    Caring for People’s Health    Page 5 of 7

LOGO    LOGO

 

looking statements, which speak only as of the date they are made. Neither OACB nor Alvotech undertakes any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech and OACB disclaim any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech, OACB or any of their respective directors, officers, employees, affiliates, agents, advisors or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.

No Offer

This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

CONTACTS

ALVOTECH

Investor Relations

Stephanie Carrington

ICR Westwicke

Stephanie.Carrington@westwicke.com(646) 277-1282

Media Relations

Sean Leous

ICR Westwicke

Sean.Leous@westwicke.com

(646) 866-4012

Corporate Communications

Alvotech.media@alvotech.com

 

STADA Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Simone Berger / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au

04/06/2021    Caring for People’s Health    Page 6 of 7

LOGO    LOGO

 

STADA

Additional information for journalists:

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18

61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

Fax: +49 (0) 6101 603-215

E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18

61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations

OAKTREE ACQUISITION CORP. II

Investor Relations

info@oaktreeacquisitioncorp.com

Media Relations

mediainquiries@oaktreecapital.com

 

STADA Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Simone Berger / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au

04/06/2021    Caring for People’s Health    Page 7 of 7
 EX-101.SCH 3 oacb-20220406.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 oacb-20220406_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 oacb-20220406_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Information [Table] Document Information [Table] Document Information [Line Items] Document Information [Line Items] Capital Units [Member] Capital Units [Member] Common Class A [Member] Common Class A [Member] Warrant [Member] Warrant [Member] EX-101.PRE 6 oacb-20220406_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g345191g18q20.jpg GRAPHIC begin 644 g345191g18q20.jpg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end GRAPHIC 8 g345191g56f03.jpg GRAPHIC begin 644 g345191g56f03.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 06, 2022
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Apr. 06, 2022
Entity Registrant Name Oaktree Acquisition Corp. II
Entity Incorporation, State or Country Code E9
Entity File Number 001-39526
Entity Tax Identification Number 98-1551592
Entity Address, Address Line One 333 South Grand Avenue
Entity Address, Address Line Two 28th Floor
Entity Address, City or Town Los Angeles
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90071
City Area Code 213
Local Phone Number 830-6300
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001820931
Capital Units [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fourth of one redeemable warrant
Trading Symbol OACB.U
Security Exchange Name NYSE
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A ordinary shares included as part of the units
Trading Symbol OACB
Security Exchange Name NYSE
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
Trading Symbol OACB WS
Security Exchange Name NYSE
XML 10 d345191d8k_htm.xml IDEA: XBRL DOCUMENT 0001820931 2022-04-06 2022-04-06 0001820931 us-gaap:CapitalUnitsMember 2022-04-06 2022-04-06 0001820931 us-gaap:CommonClassAMember 2022-04-06 2022-04-06 0001820931 us-gaap:WarrantMember 2022-04-06 2022-04-06 false 0001820931 8-K 2022-04-06 Oaktree Acquisition Corp. II E9 001-39526 98-1551592 333 South Grand Avenue 28th Floor Los Angeles CA 90071 213 830-6300 true false false false Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fourth of one redeemable warrant OACB.U NYSE Class A ordinary shares included as part of the units OACB NYSE Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 OACB WS NYSE true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 4 24 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d345191d8k.htm d345191dex991.htm oacb-20220406.xsd oacb-20220406_def.xml oacb-20220406_lab.xml oacb-20220406_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d345191d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "oacb-20220406_def.xml" ] }, "inline": { "local": [ "d345191d8k.htm" ] }, "labelLink": { "local": [ "oacb-20220406_lab.xml" ] }, "presentationLink": { "local": [ "oacb-20220406_pre.xml" ] }, "schema": { "local": [ "oacb-20220406.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 32, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 3, "nsprefix": "oacb", "nsuri": "http://www.OaktreeAcquisitionCorp.com/20220406", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d345191d8k.htm", "contextRef": "duration_2022-04-06_to_2022-04-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d345191d8k.htm", "contextRef": "duration_2022-04-06_to_2022-04-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_CapitalUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Units [Member]", "terseLabel": "Capital Units [Member]" } } }, "localname": "CapitalUnitsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.OaktreeAcquisitionCorp.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001193125-22-096828-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-096828-xbrl.zip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end